A publication in Value of Health in 2012 by Robert J. Nordyke, et al., concluded that relative to the value placed on therapeutics, the reimbursed value of CDs is a small fraction of what would be expected under value-based pricing.

Has there been an update to this study? Do the results still hold given the reimbursement environment has changed significantly since then?

Article PCN128 Estimating the Value of Companion Diagnostics: Are th...

More Nick Poulios's questions See All
Similar questions and discussions